RA Capital Management, a director, bought a $423.8M stake at $20.00 per share, establishing a new position at a price 24.8% above the 90-day low. This massive first-time investment by a major biotech-focused fund signals a high-conviction bet on the company's future, especially as it was made alongside a smaller $250K purchase by another insider. Bull: A successful hold above the $26.61 low could target a re-test of the $34.47 high, representing over 70% upside.

Where it could go — Broad base rate 62.5% positive at 90d; bull holds $26.61, bear breaks $20.00.

Director Alan Sebulsky bought $250,000 worth of PBLS stock, establishing a new position at a price 42% below the 90-day high. This first-ever buy by a long-tenured director near a low is a notable vote of confidence, though its significance is tempered by the absence of other insiders buying alongside him.

Where it could go — Analyst mean target not available; broad pattern data shows 62.5% of similar setups led to a higher stock price at 90 days.